Back to top

Analyst Blog

Amicus Therapeutics (FOLD - Snapshot Report) participated in the 32nd annual J.P. Morgan Healthcare Conference. The presentation focused on its strategic outlook and financial guidance for 2014.

Amicus’ strategy is to advance the development of next-generation Enzyme Replacement Therapies (ERTs). Amicus will enter the clinic with lead programs in Fabry, Pompe and mucopolysaccharidosis I (MPS I) in the year 2014, 2015 and 2016 respectively. The proof-of-concept preclinical data for next-generation ERTs for Fabry and Pompe will be presented in the first half of 2014.

Amicus expects cash, cash equivalents and marketable securities of $82.0 million as of Dec 31, 2013. Amicus expects 2014 net cash spend in the range of $54 million to $59 million. The company predicts that the current cash position should fund operations into the second half of 2015.  

Amicus and GlaxoSmithKline (GSK - Analyst Report) are conducting two phase III studies – FACETS Study and ATTRACT Study – to investigate migalastat HCl monotherapy in patients with Fabry’s disease. Data from FACET study is expected in the second quarter this year and the top-line data from the ATTRACT study is expected in the second half of 2014.

We note that the Amicus-Glaxo collaboration for migalastat HCl dates back to 2010. This agreement was amended in Nov 2013. As per the agreement, Amicus will have the sole worldwide rights to develop and commercialize migalastat HCl (both as monotherapy and in combination with ERT) for Fabry’s disease. 

Amcius currently carries a Zacks Rank #2 (Buy). Better-ranked stocks include Lannett Company, Inc. (LCI - Snapshot Report) and Endocyte, Inc. (ECYT - Snapshot Report). Both these stocks carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%